FDA Approves ELELYSO(TM); Auxilium To Present CCH Data For AUX-CC-867 MULTICORD
ELELYSO is therefore now indicated for long-term enzyme replacement therapy for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.
Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSOa
Pfizer and Protalix BioTherapeutics announced that the U.S. Food and Drug Administration approved ELELYSOTM for injection for pediatric patients.
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa)...
Protalix BioTherapeutics, Inc. , announced today that new clinical data on ELELYSOTM will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel.
Easier access funded enzyme replacement therapy
PHARMAC is providing greater funded access to the expensive enzyme replacement therapy imiglucerase , mainly expanding its use in children.